This trial will measure liver health improvements in people with NASH and advanced fibrosis treated with GSK4532990 compared to a placebo. It will last up to 76 weeks.
- Non-alcoholic Fatty Liver Disease
2 Primary · 20 Secondary · Reporting Duration: Pre-dose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose
3 Treatment Groups
High Dose GSK4532990
1 of 3
Low Dose GSK4532990
1 of 3
1 of 3
246 Total Participants · 3 Treatment Groups
Primary Treatment: High Dose GSK4532990 · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any adverse effects to administering Low Dose GSK4532990?
"Our risk assessment at Power has assigned GSK4532990 a safety rating of 2, as the existing clinical data confirms its relative security but falls short of demonstrating efficacy." - Anonymous Online Contributor
How many participants are involved in this clinical trial?
"Affirmative. Clinicaltrials.gov has the details of this medical study, which was launched on January 2nd 2023, and it is actively enrolling participants. A total of 246 individuals need to be recruited from two distinct sites." - Anonymous Online Contributor
Is the age limit for participants in this experiment set beyond thirty?
"This clinical trial necessitates that participants must be between 18 and 75 years of age. There are 29 studies for those under the legal age and 316 studies involving individuals over 65." - Anonymous Online Contributor
Is this research actively recruiting participants?
"Affirmative. According to clinicaltrials.gov, the trial originally posted on January 2nd 2023 is actively seeking participants. The latest update was February 8th 2023 and 246 individuals are required between two medical facilities." - Anonymous Online Contributor
Is my eligibility to join this clinical research project in any way feasible?
"This clinical trial is looking for 246 individuals, aged between 18 and 75, who are suffering from non-alcoholic fatty liver disease. Participants must also meet the following criteria: have a BMI of 25 kg/m^2 or more (or 23 kg/m^2 if Asian), demonstrate features associated with metabolic syndrome as judged by the investigator, present an NAS score >=4 with at least 1 point each in steatosis, inflammation and ballooning; Fibrosis CRN score should be 3., agree to attend all assessments required for participation in this study including a Week 52 biopsy.." - Anonymous Online Contributor